微生物疗法板块集体团灭_老虎社区_美港股上老虎

微生物疗法板块集体团灭

牛唐
2021-07-24

$Seres Therapeutics, Inc.(MCRB)$ 在中期试验中未能达到溃疡性结肠炎候选药物SER-287的主要终点，高盛给出的评级从中性下调至卖出，将目标股价下调约70.8%，至每股7.00美元。

投资者情绪围绕着其他基于微生物组的疗法和基于微生物组的药物发现平台的潜力：F$Finch Therapeutics Group, Inc.(FNCH)$ 、$Evelo Biosciences(EVLO)$ 、$Kaleido Biosciences Inc.(KLDO)$。

$新东方(EDU)$

# 下一个美股打新，会是大肉签吗？

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":174859965,"tweetId":"174859965","gmtCreate":1627091949057,"gmtModify":1627094281916,"author":{"id":3452938437060827,"authorId":3452938437060827,"authorIdStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[{"themeId":"3dedd76b82b147d9878afe8793c4b4c8","categoryId":"7ba93224048e4975aa9a5a60d7f2353b","name":"下一个美股打新，会是大肉签吗？","type":3,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/discussion&rndata={\"themeId\":3dedd76b82b147d9878afe8793c4b4c8}&rnconfig={\"headerBarHidden\": true}","description":"药明康德、红杉资本等投资的天演药业和SaaS第一中概股容联云将在本月上市，2020年上市的中概股表现优异，这两家你看好吗？","image":"https://static.tigerbbs.com/109478ac79e7b1010aba611ffde0b0b2"}],"images":[],"coverImages":[],"title":"微生物疗法板块集体团灭","extraTitle":"","html":"<html><head></head><body><a target=\"_blank\" href=\"https://laohu8.com/S/MCRB\">$Seres Therapeutics, Inc.(MCRB)$</a>&nbsp;在中期试验中未能达到溃疡性结肠炎候选药物SER-287的主要终点，高盛给出的评级从中性下调至卖出，将目标股价下调约70.8%，至每股7.00美元。投资者情绪围绕着其他基于微生物组的疗法和基于微生物组的药物发现平台的潜力：F<a target=\"_blank\" href=\"https://laohu8.com/S/FNCH\">$Finch Therapeutics Group, Inc.(FNCH)$</a>&nbsp;、<a target=\"_blank\" href=\"https://laohu8.com/S/EVLO\">$Evelo Biosciences(EVLO)$</a>&nbsp;、<a target=\"_blank\" href=\"https://laohu8.com/S/KLDO\">$Kaleido Biosciences Inc.(KLDO)$</a>。<a target=\"_blank\" href=\"https://laohu8.com/S/EDU\">$新东方(EDU)$</a>&nbsp;</body></html>","htmlText":"<html><head></head><body><a target=\"_blank\" href=\"https://laohu8.com/S/MCRB\">$Seres Therapeutics, Inc.(MCRB)$</a>&nbsp;在中期试验中未能达到溃疡性结肠炎候选药物SER-287的主要终点，高盛给出的评级从中性下调至卖出，将目标股价下调约70.8%，至每股7.00美元。投资者情绪围绕着其他基于微生物组的疗法和基于微生物组的药物发现平台的潜力：F<a target=\"_blank\" href=\"https://laohu8.com/S/FNCH\">$Finch Therapeutics Group, Inc.(FNCH)$</a>&nbsp;、<a target=\"_blank\" href=\"https://laohu8.com/S/EVLO\">$Evelo Biosciences(EVLO)$</a>&nbsp;、<a target=\"_blank\" href=\"https://laohu8.com/S/KLDO\">$Kaleido Biosciences Inc.(KLDO)$</a>。<a target=\"_blank\" href=\"https://laohu8.com/S/EDU\">$新东方(EDU)$</a>&nbsp;</body></html>","text":"$Seres Therapeutics, Inc.(MCRB)$ 在中期试验中未能达到溃疡性结肠炎候选药物SER-287的主要终点，高盛给出的评级从中性下调至卖出，将目标股价下调约70.8%，至每股7.00美元。 投资者情绪围绕着其他基于微生物组的疗法和基于微生物组的药物发现平台的潜力：F$Finch Therapeutics Group, Inc.(FNCH)$ 、$Evelo Biosciences(EVLO)$ 、$Kaleido Biosciences Inc.(KLDO)$。 $新东方(EDU)$","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/174859965","repostId":0,"isVote":1,"tweetType":1,"viewCount":2519,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MCRB","EVLO","EDU","KLDO","FNCH"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":335,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}